Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock Price Down 4.3% – What’s Next?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF)’s stock price dropped 4.3% during mid-day trading on Monday . The stock traded as low as $28.71 and last traded at $28.71. Approximately 226 shares changed hands during trading, an increase of 3% from the average daily volume of 220 shares. The stock had previously closed at $29.99.

Analyst Upgrades and Downgrades

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Price Performance

The company has a current ratio of 0.91, a quick ratio of 0.62 and a debt-to-equity ratio of 0.31. The firm has a market cap of $10.22 billion, a P/E ratio of 27.61 and a beta of 0.62. The stock’s fifty day moving average is $29.55 and its two-hundred day moving average is $29.69.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.